APPENDIX A: National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015: Tables, Figures, and Hyperlinks

Section of this NLA Annual Summary	Table/figure number and title description as found in the original publication and hyperlink	Reference
NLA Executive Summary	Table 1. Classifications of cholesterol and triglyceride Levels in mg/dL	1
	Table 2. Treatment goals for non-HDL-C, LDL-C, and Apo B in mg/dL	1
	Table 3. Criteria for ASCVD risk assessment, treatment goals for atherogenic cholesterol, and levels at which to consider drug therapy	1
	Table 7. Major risk factors for ASCVD	1
	Table 8. Criteria for classification of ASCVD	1
	Table 9. High- or very high-risk patient groups	1
	Table 10. Sequential steps in ASCVD risk assessment	1
	Table 11. Risk indicators (other than major ASCVD risk factors) that might be considered for risk refinement	1
Genetics and Classification of Dyslipidemia	Figure 5. Refrigerated plasma portion of test tubes of blood drawn from three dyslipidemic patients.	3
	Table 1. Genetic classification of dyslipidemia.	*
	Table 2. Genetic causes of hypolipidemias	*
Evaluation and Management of Familial Hypercholesterolemia	Table 3: Simon Broome diagnostic criteria for familial hypercholesterolemia	*
	Table 4. Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolemia	*
	Table 5. MEDPED diagnostic criteria for heterozygous familial hypercholesterolemia	*
	Table Summary Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia	8
Secondary Causes of Dyslipidemia	Table 6. Secondary causes of dyslipidemia due to disordered metabolism or disease	*
	Table 7. Secondary causes of dyslipidemia due to drugs	*
Medical Nutrition Therapy	Table 8. Nutritional content, characteristics and diseases/disorders/altered metabolic states that may elevate LDL-C and/or triglyceride concentrations	*

(continued on next page)

APPENDIX A (continued)

Section of this NLA Annual Summary	Table/figure number and title description as found in the original publication and hyperlink	Reference
Physical Activity	Table 9. Physical exercise recommendations for improvement in lipid levels	*
	Table 10. Primary factors influencing exercise-generated weight loss and exercise training lipid/lipoprotein response	*
Obesity, Adiposopathy, Metabolic Syndrome, and Diabetes Mellitus	Table 1. Adiposopathy ("sick fat"): summary of causality and examples of anatomic, pathophysiologic, and clinical manifestations	15
	Figure 3. Adiposopathy in the fasting state and the contribution to the lipid pattern typically found with the metabolic syndrome	15
	Figure 4. Inter-relationship between adiposopathy, type 2 diabetes mellitus, dyslipidemia, and atherosclerosis	15
	Table 1. Metabolic syndrome definitions.	48
	Table 4. Examples of Endocrine and Immune Adipocyte and Adipose Tissue Factors as Potential Contributors to "Adiposopathic Dyslipidemia."	15
	Table 11. Non-weight management pharmaceuticals that that may affect body weight.	*
Statin & Non-Statin Pharmacotherapy	Table 12. Intensity of statin therapy	1
	Table 3. Focus on ASCVD risk reduction: 4 statin benefit groups	58
	Table 13. Drugs affecting lipoprotein metabolism	1
Lipid-Altering Drug Prescribing Information	Atorvastatin: http://labeling.pfizer.com/ShowLabeling.aspx?id5587	NA
	Simvastatin: http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf	NA
	Pravastatin: http://packageinserts.bms.com/pi/pi_pravachol.pdf	NA
	Fluvastatin: https://www.pharma.us.novartis.com/product/pi/pdf/Lescol.pdf	NA
	Mevacor: http://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_pi.pdf	NA
	Pitavastatin: http://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf	NA
	Ezetimibe: http://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf	NA
	Omega-3-acid ethyl esters (EPA and DHA): https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF	NA
	Icosapent ethyl (EPA only): http://www.vascepa.com/full-prescribing-information.pdf	NA
	Omega-3-carboxylic acids (EPA and DHA free fatty acid formulation): http://www1.astrazeneca-us.com/pi/epanova.pdf	NA
	Colesevelam HCl: http://dsi.com/prescribing-information-portlet/getDocument?product=WC&inline=true	NA
	Cholestyramine: http://www.rxlist.com/questran-drug/side-effects-interactions.htm	NA
	Colestipol: http://www.rxlist.com/colestid-drug/side-effects-interactions.htm	NA
	Fenofibrate: http://www.rxlist.com/tricor-drug/side-effects-interactions.htm	NA
	Fenofibric acid: http://www.rxabbvie.com/pdf/trilipix_pi.pdf	NA
	Gemfibrozil: http://www.rxlist.com/lopid-drug/side-effects-interactions.htm	NA
	Extended-release niacin: http://www.rxabbvie.com/pdf/niaspan.pdf	NA
	Lomitapide: http://www.juxtapidremsprogram.com/_pdf/012187_JuxtapidPI_8.5x11_FIN.PDF	NA
	Mipomersen: http://www.kynamro.com/w/media/Kynamro/Files/KYNAMRO-PI.pdf	NA

(continued on next page)

APPENDIX A (continued)

Section of this NLA Annual Summary	Table/figure number and title description as found in the original publication and hyperlink	Reference
Statin safety: Muscle	Table 1. Spectrum of statin-associated muscle adverse events (page S60)	74
	Table 12. Non-statin causes of elevated muscle enzymes	*
	Table 4. Diagnostic criteria for myopathy (page S65)	74
	Table 5. Indications for skeletal muscle biopsy (page S67)	74
	Figure 2. Algorithm for the evaluation of statin-associated muscle injury (page S68)	74
Statin safety: Liver	Table 1. Hy's law criteria (page S49)	74
	Table 2. Questions addressed by liver experts in the 2006 and 2014 National Lipid Association Statin Safety Task Force Reports (page S50)	74
	Table 3. Illustrative causes of elevated liver enzymes in adolescents and adults (page S52)	74
	Figure 1. Comprehensive approach to patients with elevated liver blood testing (transaminases ≥3 times the upper limits of normal) (page S54)	74
	Figure 2. Comprehensive approach to patients with elevated liver blood testing (transaminases <3 times the upper limits of normal) (page S55)	74
Statin safety: Cognition	Figure 1. Evaluation of the patient with cognitive symptom (page S12)	74
Statin safety: Diabetes mellitus	Table 1. Criteria for screening for prediabetes and diabetes before or concurrent with initiation of statin therapy (page S23)	74
	Table 2. Criteria for the diagnosis of prediabetes and diabetes (page S26)	74
	Table 3. Summary of clinical trial evidence for CVD event reduction in patients with diabetes (page S27)	74
Statin drug interactions	Table 13. Drug metabolism basics	*
	Table 14. Phases of drug interaction	*
	Table 15. Transporter classes	*
	Table 16. Pharmacokinetic and pharmacodynamics properties of statins	*
	Figure 1. Chemical structure of statins (page S31)	74
	Figure 2. Metabolic fate of statins (S31)	74
	Table 1. Transporters and enzymes involved in statin metabolism (S32)	74
	Table 2. Membrane transporters (S33)	74
	Figure 3. A proposed ranking of significance with respect to area under the curve changes and drug-drug interaction possibilities (page S35)	74
	Table 12. Comparison of drug-drug interactions across all statins (page S41)	74
	Table 13. Dose limits of various statins with respect to various interacting medications (page S43)	74
	Table 14. Statin/fibrate combination therapy pharmacokinetic interactions (page S43)	74
Lipoprotein-apheresis	Table 14. LDL apheresis	1
Biomarkers and "Advanced Lipid Testing"	Table 1. Summary recommendations for measurement of inflammatory markers and advanced lipoprotein/subfraction testing in initial clinical assessment and on treatment management decisions.	16
Health Information Technology and Electronic Medical Records	About the National Quality Strategy: Three aims; six priorities	NA
	Table 1. National Quality Forum-endorsed lipid measures	141
	Table 4. Determinants of adherence/non-adherence and persistence/poor persistence	141

NA, not applicable
*Online NLA Resource Center.